
CLAIMS

1. A compound of formula (I):



(I)

wherein:

X is $-CH_2-$, -CH(OH)-, -CH(OR')- or –C(R'R'')-, wherein:

R' is C_1-C_6 alkyl and **R''** is hydrogen or C_1-C_6 alkyl;

Ar is aryl or heteroaryl optionally substituted with one or more substituents independently selected from halogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO_2R10, NHSOR10, $NHSO_2$R10, R8R9N-C_1-C_6 alkyl, R8O-C_1-C_6 alkyl, an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein:

R4 is hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NR5R6, OR7, SR7, R8R9N-C_1-C_6 alkyl, R8O-C_1-C_6 alkyl, an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl;

R5 and **R6** are independently hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl, an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl, or R5 and R6, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted heterocyclyl group;

R7 is hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, COR4, SOR10, SO_2R10, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl, an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein R4 is as defined above;

R8 and **R9** are independently hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, COR4, an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl,

heterocyclyl, aryl or heteroaryl, or R8 and R9, taken together with the nitrogen atom to which they are bonded, may form an optionally substituted heterocyclyl group, wherein R4 is as defined above;

R10 is hydrogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, NR5R6, OR7, R8R9N-C_1-C_6 alkyl, R8O-C_1-C_6 alkyl, an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein R5, R6, R7, R8 and R9 are as defined above;

R is an optionally substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl;

R1, **R2** and **R3** are independently hydrogen, halogen, nitro, an optionally substituted straight or branched C_1-C_6 alkyl, NR5R6, or OR7, wherein R5, R6 and R7 are as defined above;

or isomers, tautomers, prodrugs or pharmaceutically acceptable salt thereof.

2. A compound of formula (I) as defined in claim 1 wherein:

X is -CH_2-, -CH(OH)-, -CH(OR')- or –C(R'R'')-, wherein R' is C_1-C_3 alkyl and R'' is hydrogen or C_1-C_3 alkyl,;

R is an optionally substituted C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl, and

R1, R2 and R3 are independently hydrogen, halogen or hydroxy.

3. A compound of formula (I) as defined in claims 1 or 2 wherein:


X is -CH_2-, -CH(OH)-, -CH(OR')- or –C(R'R'')-, where R' is methyl and R'' is hydrogen or methyl, and

R1, R2 and R3 are hydrogen.

4. A compound of formula (I) as defined in claims 1 to 3 wherein:

R is an optionally substituted ary or heteroaryl.


5. A compound of formula (I) as defined in claims 1 to 4, wherein Ar is a group of formula:



wherein Ra, Rb and Rc are independently hydrogen, halogen, C_2-C_6 alkenyl, C_2-C_6 alkynyl, cyano, nitro, NHCOR4, COR4, NR5R6, NR5COR4, OR7, SR7, SOR10, SO_2R10, NHSOR10, $NHSO_2$R10, R8R9N-C_1-C_6 alkyl, R8O-C_1-C_6 alkyl, an optionally

further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein R4, R5, R6, R7, R8, R9 and R10 are as defined above and R is an optionally substituted aryl.

6. A compound of formula (I) as defined in claims 1 to 5, wherein Ar is a group of formula:



wherein Ra is hydrogen, halogen, nitro, NHCOR4 or NR5R6 and Rb is hydrogen, nitro, NR5R6, OR7 or R8R9N-C_1-C_6 alkyl wherein R4, R5, R6, R7, R8 and R9 are as defined above.

7. A compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claims 1 to 6 which is selected from the group consisting of:

N-(5-benzyl-1H-indazol-3-yl)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(2,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-nitrobenzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-nitro-benzamide;

2-amino-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

2-amino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(2,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5 difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(1-methyl-piperidin-4-ylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(1-methyl-piperidin-4-ylamino)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

2-cyclohexylamino-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

2-cyclohexylamino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(4-hydroxy-cyclohexylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(4-hydroxy-cyclohexylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-isobutylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-isobutylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

2-benzylamino-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

2-benzylamino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-((S)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-((S)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(3-fluoro-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(3-fluoro-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-phenylamino-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-phenylamino-benzamide;

1H-pyrrole-2-carboxylic acid [2-[5-(3-fluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amide;

1H-pyrrole-2-carboxylic acid [2-[5-(3,5-difluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amide;

1H-pyrrole-3-carboxylic acid [2-[5-(3-fluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amid;

1H-pyrrole-3-carboxylic acid [2-[5-(3,5-difluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-methanesulfonylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-methanesulfonylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

2-fluoro-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-5-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(tetrahydro-pyran-4-ylamino)-benzamide;

2-fluoro-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-5-(2-methoxy-ethylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(2-methoxy-ethylamino)-benzamide;

4-[(3-dimethylamino-propyl)-methyl-amino]-N-[5-(3-ethoxy-benzyl)-1H-indazol-3-yl]-2-nitro-benzamide;

2-amino-4-[(3-dimethylamino-propyl)-methyl-amino]-N-[5-(3-ethoxy-benzyl)-1H-indazol-3-yl]-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-2-(2-methoxy-1-methoxymethyl-ethylamino)-benzamide;

2-amino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-2-nitro-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3-ethoxy-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-nitro-benzamide;

N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-dfluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methyl-1,4-diazepan-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-Difluoro-benzyl)-1H-indazol-3-yl]-4-[(2-dimethylamino-ethyl)-methyl-amino]-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[4-(dimethylamino)piperidin-1-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-3-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*S*)-1-methylpyrrolidin-2-yl]methoxy}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(1-methylpiperidin-4-yl)oxy]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[2-(dimethylamino)ethoxy]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(3*S*)-1-methylpyrrolidin-3-yl]oxy}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-{[*cis*-4-(trifluoromethyl)cyclohexyl]amino}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-{[*trans*-4-(trifluoromethyl)cyclohexyl]amino}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-fluoro-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-1-(piperidin-4-yl)-1*H*-pyrazole-4-carboxamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(*cis*-4-hydroxycyclohexyl)amino]-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(*trans*-4-hydroxycyclohexyl)amino]-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(2-hydroxyethyl)amino]-4-(4-methylpiperazin-1-yl)benzamide;

2-[(azetidin-3-ylmethyl)amino]-*N*-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-{[(1-methylazetidin-3-yl)methyl]amino}-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(1-methylpiperidin-4-yl)amino]-2-[tetrahydro-2*H*-pyran-4-ylamino]benzamide;

4-[(azetidin-3-ylmethyl)amino]-*N*-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(1-methylpiperidin-4-yl)amino]benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(1-methylpiperidin-4-yl)amino]-4-(morpholin-4-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-methoxy-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-5-(4-methylpiperazin-1-yl)-3-(tetrahydro-2*H*-pyran-4-ylamino)pyridine-2-carboxamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-6-(4-methylpiperazin-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)pyridine-3-carboxamide;

1-[4-{[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]carbamoyl}-3-(tetrahydro-2*H*-pyran-4-ylamino)benzyl]piperidine;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2-methoxyethyl)(methyl)amino]methyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(pyrrolidin-1-ylmethyl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(morpholin-4-ylmethyl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

4-(azetidin-1-ylmethyl)-*N*-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-fluoro-5-{[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-fluoro-5-(morpholin-4-ylmethyl)benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*R*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*R*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N^1-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-N^4-[2-(dimethylamino)ethyl]-N^4-methyl-2-(tetrahydro-2*H*-pyran-4-ylamino)benzene-1,4-dicarboxamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[4-(propan-2-yl)piperazin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N^1-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-N^4-[2-(dimethylamino)ethyl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzene-1,4-dicarboxamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(4-methylpiperazin-1-yl)carbonyl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N^1-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-N^4-(1-methylpiperidin-4-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzene-1,4-dicarboxamide;

N-[5-(2-methyl-5-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

4-(4-methylpiperazin-1-yl)-*N*-[5-(pyridin-3-ylmethyl)-1*H*-indazol-3-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-benzyl-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

ethyl 4-{[2-{[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]carbamoyl}-5-(4-methylpiperazin-1-yl)phenyl]amino}piperidine-1-carboxylate;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(piperidin-4-ylamino)benzamide;

ethyl 5-(3,5-difluorobenzyl)-3-({[4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)phenyl]carbonyl}amino)-1*H*-indazole-1-carboxylate;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-((S)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-{[(2R)-1-methylpyrrolidin-2-yl]methoxy}-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-{[(3R)-1-methylpyrrolidin-3-yl]oxy}-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-2-fluoro-5-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl}benzamide, and

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-((R)-2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-benzamide.

Preferred specific compound of the invention is:


N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide.

8. A compound of formula (I) or a pharmaceutically acceptable salt as defined in claims 1 to 7 which is :

N-[5-(3,5 difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide.


9. A process for preparing a compound of formula (I) as defined in claim 1, characterized in that the process comprises:

i) reducing a carbonyl compound of formula (II):




(II)


wherein Ar, R, R1, R2, and R3 are as defined in claim 1, to give a compound of formula (I_A), (I_B) or (I_C):



(I_A)



(I_B)




(I_C)


wherein Ar, R, R1, R2, R3 and R' are as defined in claim 1;

or


i') reacting a compound of formula (III_A), (III_B), (III_C) or (III_D):




(III_A)



(III_B)




(III_C)



(III_D)

wherein R, R1, R2, R3, R' and R'' are as defined in claim 1, with a compound of formula (IV):




(IV)


wherein Ar is as defined in claim 1 and Y represents hydroxy, or a suitable leaving group such as halogen, to give a compound of formula (I), as defined in claim 1;

or


i'') deprotecting a compound of formula ($XXII_A$), ($XXII_C$) or ($XXII_D$):



(XXII$_A$)




(XXII$_C$)




(XXII$_D$)


wherein Ar, R, R1, R2, R3, R'and R'' are as defined in claim 1 and PG is a suitable protecting group such as benzyl, p-methoxybenzyl, o,p-dimethoxybenzyl, or triphenylmethyl, to give a compound of formula (I_A), (I_C) or (I_D):



(I_A)



(I_C)




(I_D)

wherein Ar, R, R1, R2, R3, R' and R'' are as defined in claim 1,

optionally separating the resulting compound into the single isomers, converting the compound of formula (I) into a different compound of formula (I), and/or into a pharmaceutically acceptable salt if desired.


10. A process for preparing a compound of formula (I_A) according to claim 9, characterized in that the compound of formula (III_A) as defined in claim 9, is prepared according to the following steps:

j) reducing a compound of formula (XI):



(XI)

wherein R, R1, R2 and R3 are as defined in claim 1 in the presence of a suitable reagent like for example NaI and Me_3SiCl, to give a compound of formula (XIV):




(XIV)

wherein R, R1, R2 and R3 are as defined above;

or

k) reacting a boronic acid compound of formula (XV):



(XV)

wherein R1, R2 and R3 are as defined above, with a compound of formula (XVI):




(XVI)

wherein R is as defined in claim 1 and W represents a halogen atom, such as bromine or iodine, or a suitable leaving group like sulphonates, such as methanesulphonate or trifluoromethanesulphonate, or phosphates in the presence of a suitable catalyst such as a Palladium catalyst, to give a compound of formula (XIV) as defined above;


l) reacting the resulting compound of formula (XIV) with hydrazine hydrate, to give a compound of formula (III_A) as defined in claim 9.

11. A process for the preparation of a compound of formula (I_A),(I_C) or (I_D) as defined in claim 9, characterized in that a compound of formula ($XXII_A$), ($XXII_C$) or ($XXII_D$) as defined in claim 9, is prepared according to the following steps:


r) protecting a compound of formula (III_A), (III_C) or (III_D) as defined in claim 9, to give a compound of formula ($XXIV_A$), ($XXIV_C$) or ($XXIV_D$):



($XXIV_A$)




($XXIV_C$)




($XXIV_D$)

wherein R, R1, R2,R3, R' and R'' are as defined in claim 1 and PG_1 is a suitable protecting group such as trifluoroacetyl group;


s) protecting the resulting compound of formula ($XXIV_A$), ($XXIV_C$) or ($XXIV_D$), to give a copmpound of formula (XXV_A), (XXV_C) or (XXV_D):



(XXV_A)




(XXV_C)




(XXV_D)

wherein R, R1, R2,R3, R', R'' and PG_1 are as defined above and PG is as defined in claim 9;


t) removing the protecting group PG_1 from the resulting compound of formula (XXV_A), (XXV_C) or (XXV_D), to give a compound of formula ($XXVI_A$), ($XXVI_C$) or ($XXVI_D$):



($XXVI_A$)



($XXVI_C$)



($XXVI_D$)


wherein R, R1, R2, R3, R', R'' and PG are as defined above;

u) reacting the resulting compound of formula ($XXVI_A$), ($XXVI_C$) or ($XXVI_D$), with a compound of formula (IV) as defined in claim 9, to give a compound of formula ($XXII_A$), ($XXII_C$) or ($XXII_D$) as defined above.

12. A process for preparing a compound of formula (I) according to claim 9 characterized in that the optional conversion of a compound of formula (I) into another compound of formula (I), is carried out by one or more of the following reactions:

.) reducing a compound of formula (I) wherein Ar is a substituted aryl and one of the substituents is NO_2, for obtaining a compound of formula (I) wherein such substituent is NH_2 ;

..) acylating a compound of formula (I), wherein Ar is a substituted aryl and one of the substituents is NH_2, by reaction with a compound of formula (XXVII) or (XXVIII),



(XXVII) (XXVIII)

wherein R4 is as defined in claim 1 and Y is as defined in claim 9, followed by selective deprotection of the acyl group on the pyrazole ring for obtaining a compound of formula (I) wherein such substituent is a NHCOR4 or $NHSO_2R4$ residue, wherein R4 is as defined in claim 1;

…) reacting a compound of formula (I), wherein Ar is a substituted aryl and one of the substituents is NH_2, with a suitable aldehyde or ketone in the presence of a reducing agent, for obtaining a compound of formula (I), wherein such substituent is a NR5R6 group, wherein one of the R5 or R6 are hydrogen and the other is an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl, wherein R8 and R9 are as defined in claim 1.


13. A method for treating a disease caused by and/or associated with a deregulated protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined in claim 1.

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.


15. A product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, or pharmaceutical compositions thereof as defined in claim 14 and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.

16. A compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use as a medicament.


17. An intermediate of the formula (XII_A), ($XXII_C$) or ($XXII_D$):



($XXII_A$)




($XXII_C$)



($XXII_D$)

wherein Ar, R, R1, R2, R3, R'and R'' are as defined in claim 1 and PG is as defined in claim 9.

18. A compound of formula (XXVII):




(XXVII)

wherein Ar, R, R1, R2 and R3 are as defined in claim 1 and PG_2 is ethoxycarbonyl or 2-methoxyethylcarbonyl.

CLAIMS

The invention claimed is:

1. A compound of formula (I):



(I)

wherein:

X is $-CH_2-$, -CH(OH)-, -CH(OR')- or –C(R'R'')-, wherein:

R' is C_1-C_6 alkyl and **R''** is hydrogen;

Ar is phenyl, pyrazolyl or pyridyl optionally substituted with one or more substituents independently selected from halogen, nitro, COR4, OR7, NR5R6, $NHSO_2R10$, a straight or branched C_1-C_6 alkyl optionally substituted by an heterocyclyl, in its turn optionally substituted by a straight or branched C_1-C_6 alkyl or an heterocyclylalkyl, or

a heterocyclyl optionally substituted by a straight or branched C_1-C_6 alkyl, in its turn optionally substituted by a heterocyclyl or a C_1-C_6 alkoxycarbonyl, or a C_1-C_6 dialkylamino;

R4 is NR5R6, or a heterocyclyl, optionally further substituted by a straight or branched C_1-C_6 alkyl, heterocyclylalkyl, heterocyclyl, or a C_1-C_6 dialkylamino;

R5 and **R6** are independently hydrogen, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl, a straight or branched C_1-C_6 alkyl optionally further substituted by C_1-C_6 alkoxy, C_1-C_6 dialkylamino, halogen, phenyl, hydroxyl or heterocyclyl in its turn optionally substituted by alkyl, C_3-C_6 cycloalkyl optionally substituted by hydroxyl or trifluoro C_1-C_6 alkyl, heterocyclyl optionally substituted by C_1-C_6 alkyl in its turn optionally substituted by halogen or heterocyclyl, C_1-C_6 alkoxycarbonyl, C_1-C_6 dialkylamino, heterocyclyl, or phenyl,

or R5 and R6, taken together with the nitrogen atom to which they are bonded, may form a heterocyclyl group optionally substituted by a straight or branched C_1-C_6

alkyl, in its turn optionally substituted by a heterocyclyl or a C_1-C_6 alkoxycarbonyl, a C_1-C_6 dialkylamino or a heterocyclyl;

R7 is straight or branched C_1-C_6 alkyl, optionally substituted by C_1-C_6 dialkylamino or heterocyclyl in its turn substituted by C_1-C_6 alkyl;

R8 and **R9** are independently an optionally further substituted straight or branched C_1-C_6 alkyl;

R10 is an optionally further substituted straight or branched C_1-C_6 alkyl;

R is phenyl or pyridyl optionally substituted by halogen or straight or branched C_1-C_6 alkyl;

R1, **R2** and **R3** are hydrogen;

or optical isomers, tautomers or pharmaceutically acceptable salt thereof.


2. A compound of formula (I) as defined in claim 1 wherein:

X is $-CH_2-$, -CH(OH)-, -CH(OR')- or –C(R'R'')-, wherein R' is C_1-C_3 alkyl and R'' is hydrogen.

3. A compound of formula (I) as defined in claims 1 wherein:

X is $-CH_2-$, -CH(OH)-, -CH(OR')- or –C(R'R'')-, where R' is methyl and R'' is hydrogen.


4. A compound of formula (I) as defined in claim 1, wherein Ar is a group of formula:



wherein Ra, Rb and Rc are independently hydrogen, halogen, nitro, COR4, NR5R6, OR7, $NHSO_2R10$, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl, a straight or branched C_1-C_6 alkyl optionally substituted by a heterocyclyl in its turn optionally substituted by a straight or branched C_1-C_6 alkyl or a heterocyclylalkyl, or a heterocyclyl optionally substituted by a straight or branched C_1-C_6 alkyl in its turn optionally substituted by a heterocyclyl or a C_1-C_6 alkoxycarbonyl, or a C_1-C_6 dialkylamino;

wherein R4, R5, R6, R7, R8, R9 and R10 are as defined in claim 1 and R is a phenyl optionally substituted by halogen or straight or branched C_1-C_6 alkyl.

5. A compound of formula (I) as defined in claim 1, wherein Ar is a group of formula:



wherein Ra is hydrogen, halogen, nitro or NR5R6 and Rb is hydrogen, nitro, NR5R6, OR7 or R8R9N-C_1-C_6 alkyl wherein R4, R5, R6, R7, R8 and R9 are as defined in claim 1.

6. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

N-(5-benzyl-1H-indazol-3-yl)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(2,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-nitrobenzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-nitro-benzamide;

2-amino-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

2-amino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(2,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5 difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(1-methyl-piperidin-4-ylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(1-methyl-piperidin-4-ylamino)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(2,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

2-cyclohexylamino-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

2-cyclohexylamino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(4-hydroxy-cyclohexylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(4-hydroxy-cyclohexylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-isobutylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-isobutylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

2-benzylamino-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

2-benzylamino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-((S)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-((S)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-(3-fluoro-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-(3-fluoro-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-phenylamino-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-phenylamino-benzamide;

1H-pyrrole-2-carboxylic acid [2-[5-(3-fluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amide;

1H-pyrrole-2-carboxylic acid [2-[5-(3,5-difluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amide;

1H-pyrrole-3-carboxylic acid [2-[5-(3-fluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amid;

1H-pyrrole-3-carboxylic acid [2-[5-(3,5-difluoro-benzyl)-1H-indazol-3-ylcarbamoyl]-5-(4-methyl-piperazin-1-yl)-phenyl]-amide;

N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-2-methanesulfonylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-methanesulfonylamino-4-(4-methyl-piperazin-1-yl)-benzamide;

2-fluoro-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-5-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(tetrahydro-pyran-4-ylamino)-benzamide;

2-fluoro-N-[5-(3-fluoro-benzyl)-1H-indazol-3-yl]-5-(2-methoxy-ethylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(2-methoxy-ethylamino)-benzamide;

4-[(3-dimethylamino-propyl)-methyl-amino]-N-[5-(3-ethoxy-benzyl)-1H-indazol-3-yl]-2-nitro-benzamide;

2-amino-4-[(3-dimethylamino-propyl)-methyl-amino]-N-[5-(3-ethoxy-benzyl)-1H-indazol-3-yl]-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-2-(2-methoxy-1-methoxymethyl-ethylamino)-benzamide;

2-amino-N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-[(3-dimethylamino-propyl)-methyl-amino]-2-nitro-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3-ethoxy-phenyl)-hydroxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-nitro-benzamide;
N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[(3,5-difluoro-phenyl)-methoxy-methyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;
N-{5-[1-(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;
N-{5-[1-(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[(3,5-difluoro-phenyl)-ethyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1-methoxymethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(3-methoxy-propylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-difluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-methoxy-1,1-dimethyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-{5-[1-(3,5-dfluoro-phenyl)-1-methyl-ethyl]-1H-indazol-3-yl}-2-(2-fluoro-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methyl-1,4-diazepan-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-Difluoro-benzyl)-1H-indazol-3-yl]-4-[(2-dimethylamino-ethyl)-methyl-amino]-2-(tetrahydro-pyran-4-ylamino)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[4-(dimethylamino)piperidin-1-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-3-(4-methylpiperazin-1-yl)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*S*)-1-methylpyrrolidin-2-yl]methoxy}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(1-methylpiperidin-4-yl)oxy]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[2-(dimethylamino)ethoxy]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(3*S*)-1-methylpyrrolidin-3-yl]oxy}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(piperazin-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-{[*cis*-4-(trifluoromethyl)cyclohexyl]amino}benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-{[*trans*-4-(trifluoromethyl)cyclohexyl]amino}benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-fluoro-4-(4-methylpiperazin-1-yl)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-1-(piperidin-4-yl)-1*H*-pyrazole-4-carboxamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(*cis*-4-hydroxycyclohexyl)amino]-4-(4-methylpiperazin-1-yl)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(*trans*-4-hydroxycyclohexyl)amino]-4-(4-methylpiperazin-1-yl)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(2-hydroxyethyl)amino]-4-(4-methylpiperazin-1-yl)benzamide;
2-[(azetidin-3-ylmethyl)amino]-*N*-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-{[(1-methylazetidin-3-yl)methyl]amino}-4-(4-methylpiperazin-1-yl)benzamide;
N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(1-methylpiperidin-4-yl)amino]-2-[tetrahydro-2*H*-pyran-4-ylamino]benzamide;

4-[(azetidin-3-ylmethyl)amino]-*N*-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(1-methylpiperidin-4-yl)amino]benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-[(1-methylpiperidin-4-yl)amino]-4-(morpholin-4-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-methoxy-4-(4-methylpiperazin-1-yl)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-5-(4-methylpiperazin-1-yl)-3-(tetrahydro-2*H*-pyran-4-ylamino)pyridine-2-carboxamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-6-(4-methylpiperazin-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)pyridine-3-carboxamide;

1-[4-{[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]carbamoyl}-3-(tetrahydro-2*H*-pyran-4-ylamino)benzyl]piperidine;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2-methoxyethyl)(methyl)amino]methyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(pyrrolidin-1-ylmethyl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(morpholin-4-ylmethyl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

4-(azetidin-1-ylmethyl)-*N*-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-(4-methyl-piperazin-1-ylmethyl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-fluoro-5-{[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-2-fluoro-5-(morpholin-4-ylmethyl)benzamide;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-((S)-2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*R*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl}benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*S*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[(2*R*)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N^1-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-N^4-[2-(dimethylamino)ethyl]-N^4-methyl-2-(tetrahydro-2*H*-pyran-4-ylamino)benzene-1,4-dicarboxamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[4-(propan-2-yl)piperazin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N^1-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-N^4-[2-(dimethylamino)ethyl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzene-1,4-dicarboxamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-[(4-methylpiperazin-1-yl)carbonyl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N^1-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-N^4-(1-methylpiperidin-4-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)benzene-1,4-dicarboxamide;

N-[5-(2-methyl-5-fluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

4-(4-methylpiperazin-1-yl)-*N*-[5-(pyridin-3-ylmethyl)-1*H*-indazol-3-yl]-2-(tetrahydro-2*H*-pyran-4-ylamino)benzamide;

N-[5-benzyl-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide;

ethyl 4-{[2-{[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]carbamoyl}-5-(4-methylpiperazin-1-yl)phenyl]amino}piperidine-1-carboxylate;

N-[5-(3,5-difluorobenzyl)-1*H*-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(piperidin-4-ylamino)benzamide;

ethyl 5-(3,5-difluorobenzyl)-3-({[4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2*H*-pyran-4-ylamino)phenyl]carbonyl}amino)-1*H*-indazole-1-carboxylate;

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-((S)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide;

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-{[(2R)-1-methylpyrrolidin-2-yl]methoxy}-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;

N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-{[(3R)-1-methylpyrrolidin-3-yl]oxy}-2-(tetrahydro-2H-pyran-4-ylamino)benzamide;


N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-2-fluoro-5-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methyl}benzamide, and

N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-2-fluoro-5-((R)-2-pyrrolidin-1-ylmethyl-pyrrolidine-1-carbonyl)-benzamide.

7. A compound or a pharmaceutically acceptable salt of N-[5-(3,5 difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide.


8. A process for preparing a compound of formula (I) as defined in claim 1, characterized in that the process comprises:

i) reducing a carbonyl compound of formula (II):




(II)


wherein Ar, R, R1, R2, and R3 are as defined in claim 1, to give a compound of formula (I_A), (I_B) or (I_C):



(I_A)



(I_B)




(I_C)


wherein Ar, R, R1, R2, R3 and R' are as defined in claim 1;

or


i') reacting a compound of formula (III_A), (III_B), (III_C) or (III_D):




(III_A)



(III_B)




(III_C)



(III_D)

wherein R, R1, R2, R3, R' and R'' are as defined in claim 1, with a compound of formula (IV):




(IV)


wherein Ar is as defined in claim 1 is as defined in claim 1 and Y represents hydroxy, or a suitable leaving group comprising halogen, to give a compound of formula (I), as defined in claim 1;

or


i'') deprotecting a compound of formula ($XXII_A$), ($XXII_C$) or ($XXII_D$):



($XXII_A$)




($XXII_C$)




($XXII_D$)


wherein Ar, R, R1, R2, R3, R'and R'' are as defined in claim 1 and PG is a suitable protecting group comprising benzyl, p-methoxybenzyl, o,p-dimethoxybenzyl, or triphenylmethyl, to give a compound of formula (I_A), (I_C) or (I_D):



(I_A)



(I_C)




(I_D)

wherein Ar, R, R1, R2, R3, R' and R'' are as defined in claim 1,

optionally separating the resulting compound into the single optical isomers, converting the compound of formula (I) into a different compound of formula (I), and/or into a pharmaceutically acceptable salt if desired.


9. A process for preparing a compound of formula (I_A) according to claim 8, characterized in that the compound of formula (III_A) as defined in claim 8, is prepared according to the following steps:

j) reducing a compound of formula (XI):



(XI)

in the presence of a suitable reagent comprising NaI and Me_3SiCl, to give a compound of formula (XIV):




(XIV)

wherein R, R1, R2 and R3 are as defined above;

or

k) reacting a boronic acid compound of formula (XV):



(XV)

wherein R1, R2 and R3 are as defined above, with a compound of formula (XVI):




(XVI)

wherein W represents a halogen atom, comprising bromine or iodine, or a suitable leaving group like sulphonates, comprising methanesulphonate or trifluoromethanesulphonate, or phosphates in the presence of a suitable catalyst comprising a Palladium catalyst, to give a compound of formula (XIV) as defined above;


l) reacting the resulting compound of formula (XIV) with hydrazine hydrate, to give a compound of formula (III_A) as defined in claim 8.

10. A process for the preparation of a compound of formula (I_A),(I_C) or (I_D) as defined in claim 8, characterized in that a compound of formula ($XXII_A$), ($XXII_C$) or ($XXII_D$) as defined in claim 8, is prepared according to the following steps:


r) protecting a compound of formula (III_A), (III_C) or (III_D) as defined in claim 8, to give a compound of formula ($XXIV_A$), ($XXIV_C$) or ($XXIV_D$):



($XXIV_A$)




($XXIV_C$)




($XXIV_D$)

wherein PG_1 is a suitable protecting group comprising trifluoroacetyl group;


s) protecting the resulting compound of formula ($XXIV_A$), ($XXIV_C$) or ($XXIV_D$), to give a compound of formula (XXV_A), (XXV_C) or (XXV_D):



(XXV_A)




(XXV_C)




(XXV_D)

wherein R, R1, R2, R3, R', R'' and PG_1 are as defined above and PG is as defined in claim 8;


t) removing the protecting group PG_1 from the resulting compound of formula (XXV_A), (XXV_C) or (XXV_D), to give a compound of formula ($XXVI_A$), ($XXVI_C$) or ($XXVI_D$):



($XXVI_A$)



($XXVI_C$)



($XXVI_D$)

wherein R, R1, R2, R3, R', R'' are as defined in claim 1 and PG is defined in claim 8;

u) reacting the resulting compound of formula ($XXVI_A$), ($XXVI_C$) or ($XXVI_D$), with a compound of formula (IV) as defined in claim 8, to give a compound of formula ($XXII_A$), ($XXII_C$) or ($XXII_D$) as defined in claim 8.

11. A process for preparing a compound of formula (I) according to claim 8 characterized in that the optional conversion of a compound of formula (I) into another compound of formula (I), is carried out by one or more of the following reactions:

.) reducing a compound of formula (I) wherein Ar is a substituted aryl and one of the substituents is NO_2, for obtaining a compound of formula (I) wherein such substituent is NH_2 ;

..) acylating a compound of formula (I), wherein Ar is a substituted aryl and one of the substituents is NH_2, by reaction with a compound of formula (XXVII) or (XXVIII),



(XXVII) (XXVIII)


followed by selective deprotection of the acyl group on the pyrazole ring for obtaining a compound of formula (I) wherein such substituent is a NHCOR4 or $NHSO_2R4$ residue;

...) reacting a compound of formula (I), wherein Ar is a substituted aryl and one of the substituents is NH_2, with a suitable aldehyde or ketone in the presence of a reducing agent, for obtaining a compound of formula (I), wherein such substituent is a NR5R6 group, wherein one of the R5 or R6 are hydrogen and the other is an optionally further substituted straight or branched C_1-C_6 alkyl, C_3-C_6 cycloalkyl, heterocyclyl, aryl, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl.


12. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, and at least one pharmaceutically acceptable excipient, carrier and/or diluent.

13. A product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, or pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, and at least one pharmaceutically acceptable excipient, carrier and/or diluent and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.


14. An intermediate of the formula ($XXII_A$), ($XXII_C$) or ($XXII_D$):



($XXII_A$)



($XXII_C$)



($XXII_D$)

wherein R' is C_1-C_6 alkyl and R'' is hydrogen;

Ar is phenyl, pyazolyl or pyridyl optionally substituted with one or more substituents independently selected from

halogen, nitro, COR4, OR7, NR5R6, $NHSO_2R10$,

a straight or branched C_1-C_6 alkyl optionally substituted by an heterocyclyl, in its turn optionally substituted by a straight or branched C_1-C_6 alkyl or an heterocyclylalkyl, or

a heterocyclyl optionally substituted by a straight or branched C_1-C_6 alkyl, in its turn optionally substituted by a heterocyclyl or a C_1-C_6 alkoxycarbonyl,

or a C_1-C_6 dialkylamino;

R4 is NR5R6, or a heterocyclyl, optionally further substituted by a straight or branched C_1-C_6 alkyl, heterocyclylalkyl, heterocyclyl, or a C_1-C_6 dialkylamino;

R5 and R6 are independently hydrogen, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl,

a straight or branched C_1-C_6 alkyl optionally further substituted by C_1-C_6 alkoxy, C_1-C_6 dialkylamino, halogen, phenyl, hydroxyl or heterocyclyl in its turn optionally substituted by alkyl,

C_3-C_6 cycloalkyl optionally substituted by hydroxyl or trifluoro C_1-C_6 alkyl,

heterocyclyl optionally substituted by C_1-C_6 alkyl in its turn optionally substituted by halogen or heterocyclyl, C_1-C_6 alkoxycarbonyl, C_1-C_6 dialkylamino, heterocyclyl, or phenyl,

or R5 and R6, taken together with the nitrogen atom to which they are bonded, may form a heterocyclyl group optionally substituted by a straight or branched C_1-C_6 alkyl, in its turn optionally substituted by a heterocyclyl or a C_1-C_6 alkoxycarbonyl, a C_1-C_6 dialkylamino or a heterocyclyl;

R7 is straight or branched C_1-C_6 alkyl, optionally substituted by C_1-C_6 dialkylamino or heterocyclyl in its turn substituted by C_1-C_6 alkyl;

R8 and R9 are independently an optionally further substituted straight or branched C_1-C_6 alkyl;

R10 is an optionally further substituted straight or branched C_1-C_6 alkyl;


R is phenyl or pyridyl optionally substituted by halogen or straight or branched C_1-C_6 alkyl;

R1, R2 and R3 are hydrogen;

or optical isomers, tautomers or pharmaceutically acceptable salt thereof,

and PG is a suitable protecting group comprising benzyl, p-methoxybenzyl, o,p-dimethoxybenzyl, or triphenylmethyl.

15. A compound of formula (XXVII):



(XXVII)

wherein R' is C_1-C_6 alkyl and R'' is hydrogen;

Ar is phenyl, pyazolyl or pyridyl optionally substituted with one or more substituents independently selected from

halogen, nitro, COR4, OR7, NR5R6, $NHSO_2R10$,

a straight or branched C_1-C_6 alkyl optionally substituted by an heterocyclyl, in its turn optionally substituted by a straight or branched C_1-C_6 alkyl or an heterocyclylalkyl, or

a heterocyclyl optionally substituted by a straight or branched C_1-C_6 alkyl, in its turn optionally substituted by a heterocyclyl or a C_1-C_6 alkoxycarbonyl,

or a C_1-C_6 dialkylamino;

R4 is NR5R6, or a heterocyclyl, optionally further substituted by a straight or branched C_1-C_6 alkyl, heterocyclylalkyl, heterocyclyl, or a C_1-C_6 dialkylamino;

R5 and R6 are independently hydrogen, R8R9N-C_2-C_6 alkyl, R8O-C_2-C_6 alkyl,

a straight or branched C_1-C_6 alkyl optionally further substituted by C_1-C_6 alkoxy, C_1-C_6 dialkylamino, halogen, phenyl, hydroxyl or heterocyclyl in its turn optionally substituted by alkyl,

C_3-C_6 cycloalkyl optionally substituted by hydroxyl or trifluoro C_1-C_6 alkyl,

heterocyclyl optionally substituted by C_1-C_6 alkyl in its turn optionally substituted by halogen or heterocyclyl, C_1-C_6 alkoxycarbonyl, C_1-C_6 dialkylamino, heterocyclyl, or phenyl,

or R5 and R6, taken together with the nitrogen atom to which they are bonded, may form a heterocyclyl group optionally substituted by a straight or branched C_1-C_6 alkyl, in its turn optionally substituted by a heterocyclyl or a C_1-C_6 alkoxycarbonyl, a C_1-C_6 dialkylamino or a heterocyclyl;

R7 is straight or branched C_1-C_6 alkyl, optionally substituted by C_1-C_6 dialkylamino or heterocyclyl in its turn substituted by C_1-C_6 alkyl;

R8 and R9 are independently an optionally further substituted straight or branched C_1-C_6 alkyl;

R10 is an optionally further substituted straight or branched C_1-C_6 alkyl;

R is phenyl or pyridyl optionally substituted by halogen or straight or branched C_1-C_6 alkyl;


R1, R2 and R3 are hydrogen;

or optical isomers, tautomers or pharmaceutically acceptable salt thereof,

and PG_2 is ethoxycarbonyl or 2-methoxyethylcarbonyl.

16. A process for preparing a compound of formula (XXVII) as defined in claim 15, characterized in that the process comprises:

v) protecting a compound of formula (I) as defined in claim 1, to give a compound of formula (XXVII):



(XXVII)

wherein Ar, R, R1, R2 and R3 and PG_2 is as defined in claim 15.